🇺🇸 FDA
Pipeline program

LCZ696 (sacubitril/valsartan)

CLCZ696G2301

Phase 3 small_molecule completed

Quick answer

LCZ696 (sacubitril/valsartan) for Acute Myocardial Infarction is a Phase 3 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Pharmaceuticals
Indication
Acute Myocardial Infarction
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials